RVTY · Earnings event · Q2 2026 · archived
Revvity (RVTY) Q2 2026 earnings — TrendMatrix coverage
Reported · EPS $1.41 vs estimate $1.22 (+15.9%) — classified BEAT.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Event detail · Q2 2026
EPS beat/miss and revenue
| Metric | Estimate | Actual | Surprise |
|---|---|---|---|
| EPS (diluted) | $1.22 | $1.41 | +15.9% |
| Revenue | — | — | — |
Verdict reaction
How the verdict moved around this report
Before this report, TrendMatrix rated RVTY Hold at 5.2/10. After the Q2 2026 report, the verdict moved to Buy (Wait) at 5.3/10.
Healthcare context
RVTY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $13.04B
- P/E (fwd)
- 19.8
- P/E (ttm)
- 56.2
- 52-week range
- $81.22–$118.34
- Off 52-week high
- 1.3%
- RSI (14)
- 69
- Volume vs avg
- 0.49×
- Engine score
- 4.9/10
Live context at TrendMatrix’s latest engine read — updates after the report date; not frozen to it.